Published January 2013 | 17 Pages | 30 Exhibits |
All companies include technology, market(s), key executive, and contact information.
Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies
This report is included in LSI's Emerging Medical Technologies® Database.
•Personal genome service that enables users to: search and explore genes contributing to their personal characteristics, such as lactose intolerance, athletic ability, and food preferences; learn how the research studies relate to their genomes; compare their profiles to family and friends; and discover their genetic roots
•1-Line of proprietary drugs that are approved by the Ministry of Health of Russian Federation and 2-Contract manufacturing of generic antibiotics and specialty pharmaceuticals
•1-New, non-invasive diagnostic system to detect early-stage Alzheimer's Disease (AD) and 2-Drugs for AD and Fragile X Syndrome
•1-Point-of-care platform and a pipeline of novel diagnostic tests, including those for prostate cancer, total PSA, Vitamin D, and Alzheimer's disease and 2-Drugs to treat a wide variety of conditions
•A broad portfolio of injectable drug delivery systems which are designed for pharmaceutical manufacturers to fill with their injectable drugs and vaccines
•A high-intensity, non-focused therapeutic ultrasound catheter system for remote tissue ablation for the treatment of hypertension by renal denervation (RDN)
•A nitinol mesh sleeve that, when placed over a saphenous vein graft during coronary artery bypass grafting (CABG) surgery, is designed to improve the structural characteristics and long-term performance of the vein graft
•A rapid, user-friendly, real-time, and cost-effective technology platform that provides for accurate intraoperative placement of hip & knee implants and is compatible with all currently marketed implants
•A selective-heating technology to combine the clinical benefits of heat (hyperthermia) and chemotherapy for more effective, safer, and less expensive cancer treatments
•A suite of accessory devices to address the clinical needs of emerging interventional cardiology procedures, such as transcathether aortic valve replacement (TAVR)
•Advanced instrumentation to accelerate regenerative medicine, tissue engineering, and cell therapy experimentation
•An ultrasound device for the non-invasive treatment for refractory glaucoma
•Biomarker test kit for rheumatoid arthritis (RA) treatment
•Blood-based test to enable the earlier diagnosis of Autism Spectrum Disorders (ASDs)
•Broadly applicable molecular diagnostics and immunodiagnostics solutions (instruments, analytical techniques, chemistries, sample preparation and other innovative tools) with high-value clinical assay menus
•Catheter-based system for the minimally invasive replacement of the aortic valve for the treatment of Congestive Heart Failure (CHF)
•Cell-based technologies for treating a range of major clinical diseases, including inflammatory and immunologic conditions, diabetes and its complications, orthopedic spine conditions, cardiovascular disorders, bone marrow transplantation, and eye diseases
•Class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, hematology, oncology, and pulmonary disease
•Convenient two-component subcutaneous drug delivery system suitable for patient self-administration
•Devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders
•Human cell-based therapies for the treatment of retinal and neural degenerative diseases such as macular degeneration, Parkinson's Disease (PD), and Multiple Sclerosis (MS)
•Image-guided therapy systems which deliver detailed visual information to clinicians during the course of various traditional surgical procedures, including neurological, cardiovascular, cerebrovascular, interventional, and spine
•Molecularly-targeted in vivo imaging technologies
•Neural-like cells derived from bone marrow for autologous brain transplantation in patients with highly debilitating neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD), and Multiple Sclerosis (MS)
•Next-generation bio-regenerative implant coatings for orthopedic and dental applications
•Novel surfactant therapies, as well as effective and efficient modes of delivery, to advance a new standard in respiratory critical care
•Platform that identifies the master switches for disease genes, opening a whole new approach to novel therapeutics for cancer and other diseases
•Sample-to-result technology and products that provide multiple-pathogen diagnoses of infectious diseases
•The only non-cutting liposuction technology
•Unique bioactive and coating-free coronary stent as an alternative to drug-eluting stents (DES) with the potential to increase patient safety while allowing a significant reduction in Dual Anti-Platelet Treatment (DAPT) time
We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
